Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in TNBC
NCT04676997Phase 2Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- May 2020
- Primary completion
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in triple-negative breast cancer (TNBC), sponsored by Shandong Cancer Hospital. Primary endpoint: Pathological Complete Response (ypT0/Tis ypN0). Status: unknown.
02
Drugs
camrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04676997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676997.